Stonepine Capital Management as of June 30, 2023
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 19 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Quidel Corp (QDEL) | 19.3 | $51M | 619k | 82.86 | |
| Evolus (EOLS) | 12.3 | $33M | 4.5M | 7.27 | |
| Adma Biologics (ADMA) | 12.2 | $32M | 8.8M | 3.69 | |
| Galapagos Nv- Spon Adr (GLPG) | 10.4 | $28M | 683k | 40.66 | |
| Amylyx Pharmaceuticals (AMLX) | 9.1 | $24M | 1.1M | 21.57 | |
| Maxcyte (MXCT) | 6.8 | $18M | 4.0M | 4.59 | |
| Xeris Pharmaceuticals (XERS) | 5.4 | $14M | 5.5M | 2.62 | |
| Third Harmonic Bio (THRD) | 5.0 | $13M | 2.8M | 4.81 | |
| Atyr Pharma Com New (LIFE) | 3.8 | $10M | 4.6M | 2.16 | |
| Scynexis Com New (SCYX) | 3.3 | $8.7M | 2.9M | 2.95 | |
| Xoma Corp Com New (XOMA) | 2.5 | $6.6M | 349k | 18.89 | |
| Rezolute Com New (RZLT) | 2.3 | $6.1M | 3.1M | 1.98 | |
| Tela Bio (TELA) | 1.8 | $4.9M | 483k | 10.13 | |
| Urogen Pharma (URGN) | 1.7 | $4.6M | 449k | 10.35 | |
| Exagen (XGN) | 1.1 | $3.0M | 1.0M | 2.90 | |
| Gamida Cell SHS (GMDA) | 1.1 | $2.9M | 1.5M | 1.93 | |
| Atea Pharmaceuticals (AVIR) | 1.1 | $2.8M | 752k | 3.74 | |
| Castle Biosciences (CSTL) | 0.5 | $1.3M | 92k | 13.72 | |
| Aytu Biopharma (AYTU) | 0.3 | $756k | 472k | 1.60 |
